

AD \_\_\_\_\_

Award Number: DAMD17-00-1-0320

TITLE: The Role of S100A7/RANBPM Interaction in Human Breast  
Cancer

PRINCIPAL INVESTIGATOR: Ethan Emberley  
Doctor Peter Watson

CONTRACTING ORGANIZATION: University of Manitoba  
Winnipeg, Manitoba R3E 0W3 Canada

REPORT DATE: August 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030411 044

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> August 2002	<b>3. REPORT TYPE AND DATES COVERED</b> Annual Summary (1 Jul 01 - 1 Jul 02)	
<b>4. TITLE AND SUBTITLE</b> The Role of S100A7/RANBPM Interaction in Human Breast Cancer			<b>5. FUNDING NUMBERS</b> DAMD17-00-1-0320	
<b>6. AUTHOR(S)</b> Ethan Emberley Doctor Peter Watson				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Manitoba Winnipeg, Manitoba R3E 0W3 Canada  E-Mail: umember0@cc.umanitoba.ca			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b> Original contains color plates. All DTIC reproductions Will be in black and white.				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. Abstract (Maximum 200 Words)</b> The purpose of this study is to determine the role of psoriasin (S100A7) in breast cancer. We began by identifying potential interacting partners for psoriasin and then examined the importance of these interactions in breast cells. We first studied the interaction of psoriasin with RanBPM and although we could confirm their interaction invitro, the same could not be said for invivo. RanBPM mRNA expression was found to be much higher in cancer cell lines than fibroblast and normal epithelia cell lines. In a cohort of 64 breast tumors, RanBPM expression was found not to correlate with any parameter, while psoriasin was found to be highly associated with Estrogen Receptor negativity and inflammation. We found that transcription of RanBPM could be induced in primary peripheral lymphocytes by stimulating with PHA. Further characterization of the RanBPM-psoriasin interaction may lead to a better understanding of the process of invasion.				
<b>14. SUBJECT TERMS</b> breast cancer, ductal carcinoma InSitu, invasion, S100, psoriasin			<b>15. NUMBER OF PAGES</b> 25	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

# **Table of Contents**

**Cover- 1**

**SF 298- 2**

**Table of Contents- 3**

**Introduction- 4**

**Body- 5-8**

**Key Research Accomplishments- 9**

**Reportable Outcomes- 10**

**Conclusions- 11**

**Appendices- 12-25**

## Introduction

We have previously identified the psoriasin gene (S100A7) as highly expressed in pre-invasive breast cancer and subsequently found that persistent psoriasin expression in invasive breast cancer is associated with markers of poor prognosis. The S100 proteins are calcium-binding proteins that may influence several cellular activities such as growth, chemotaxis, adhesion and cytoskeletal activity. The function of psoriasin and its influence in breast cancer is unknown. However *in vitro* and *in vivo* study of its role in psoriasis and also in breast tumors suggests that one possible role may be to influence the inflammatory response as a secreted chemotactic factor. We and others have also observed nuclear and cytoplasmic expression within squamous and breast epithelial cells, which raises the possibility of an additional function within epithelial cells. We therefore sought to pursue a possible intracellular function by utilizing the yeast 2-hybrid approach to screen a normal human breast expression library for intracellular breast epithelial proteins that might interact with psoriasin and that might offer insights into its functional role in breast tumor progression. We have identified two proteins that psoriasin can potentially form an interaction with, RanBPM and Jab1. The aim is to understand the importance of psoriasin expression in pre-invasive disease as well as any molecular mechanisms that it may operate through to exert its effects on the process of invasion.

# Body

## Original Statement of Work

	AIM 1.
1-6	Construct RanBPM and S100A7 – epitope tagged expression constructs
6-12	Conduct transient transfection assays with RanBPM and S100A7 to co localize using confocal microscopy and study biochemical interaction by immunoprecipitation
	AIM 2
1-6	Construct RanBPM expression constructs for inducible stable transfection (T Rex system vectors)
6-12	Stable transfection of MCF7 cell line
12-36	Analysis of effect of overexpression to RanBPM on growth, polarity, motility and invasion.
	AIM 3
1-6	Construct RanBPM in-situ hybridisation probes for tissue analysis
12-36	Examine cell type, localization and level of expression of RanBPM and relation to S100A7 expression by in-situ hybridization and RT-PCR in a panel of pre-invasive and invasive breast tumors.

---

### Aim 1.

To study the psoriasin –RanBPM interaction, I had cloned the RanBPM cDNA sequence into several expression vectors which would generate epitope tagged fusion proteins. This strategy was used because there are several antibodies commercially available to the various tags, where none existed for RanBPM. These constructs included one which generated a fusion protein of RanBPM with a C-terminal FLAG epitope tag, another which created a protein containing a N-terminal His and Xpress tag. Both vectors contained a mammalian promoter for high levels of transcription *in vivo*. Unfortunately, many attempts to achieve RanBPM expression using these constructs transfected into several types of cultured cells failed.

The construct containing the N-terminal His and Xpress tags has a T7 promoter allowing for transcription and translation *in vitro*. Using this alternative *in-vitro* strategy we were able to generate RanBPM protein and to demonstrate that the interaction (first identified by yeast 2-hybrid assay) could occur *in-vitro* (see manuscript in Appendix Fig2).

### AIM2.

We next generated a new expression construct using a tetracycline inducible plasmid system in order to express untagged but inducible RanBPM. To detect the expected RanBPM protein we also tried to make a polyclonal antibody against RanBPM using the

epitope described by Nakamura and colleagues (J Cell Biol 1998 Nov 16;143(4):1041-52). Unfortunately, the antibody did not detect either transfected, invitro generated or endogenous RanBPM. We think this is due to the poor antigenicity of the epitope as many non-specific bands were detected. This finding was also confirmed soon after our own attempt in another series of experiments by the group that originally described RanBPM (Nishitani H et. al, Gene 2001 Jul 11;272(1-2):25-33). For all constructs, detection of mRNA produced by the transfected construct was examined and confirmed by RT-PCR. Using vector specific primers, we were able to detect mRNA produced from the transgene, although at low levels which may be due to low transfection efficiency.

Recently, a report was published that found the RanBPM protein was larger than originally described on the basis of the new finding of a 5' sequence that was presumed to be a non-coding regulatory region of the gene in fact contains coding sequence. All of our expression constructs do not contain the new N-terminal piece and therefore may not represent the true RanBPM cDNA.

### Aim 3.

We have examined RanBPM mRNA expression in a series of cell lines and breast tumors initially by Real-time RT-PCR before attempting in-situ hybridization. This assay is not dependant on the change in the size of the open reading frame or translated protein as our primers also detect the longer RanBPM. In the cell lines, expression was significantly higher in cells derived from tumors compared to cells representative of normal epithelia and fibroblasts (see manuscript in Appendix Fig3). In a selected series of 80 tumors, higher RanBPM expression was seen in tumors that were Estrogen Receptor positive and had lower expression of psoriasin. Expression of psoriasin in the tumor series was correlated with increased levels of inflammation (see manuscript in Appendix Table1), so we examined RanBPM mRNA expression in human peripheral blood mononuclear lymphocytes. It was found that the polyclonal activator PHA which elicits dominantly Th2 associated cytokine response induced RanBPM mRNA production compared to polyclonal activators that elicit Th1 dominated immunity (anti-CD3, TSST-1) or cytokine production by antigen presenting cells that is Th1 inducing (LPS, SAC). No significant differences were apparent in RanBPM expression between male (n=3) and female (n=2) subjects in this sample (see manuscript in Appendix Fig4).

### Future Directions.

We have therefore completed most of aims 1 and 3, and initiated experiments for aim 2. However we have run into roadblocks with our studies of RanBPM (failure to develop an antibody or achieve in-vivo expression with the originally described cDNA) and learnt that the originally described cDNA that we had focused our studies on, is not the full length RanBPM. More importantly the full length RanBPM was not shown to have the same biological effects as originally described and therefore should now be regarded as a gene of unknown function (although a very recent paper suggests it may be involved in signal transduction).



While we are considering this information about RanBPM, and the uncertainty as to its function, we went back to review the results of our 2-hybrid screen for proteins interacting with psoriasin and from which RanBPM was isolated. We found that much

more was now known about the identity and function of another interacting protein, Jab1 (c-jun activation domain-binding protein-1) that we had also identified. We have therefore decided to enter into negotiations to modify the statement of work to pursue the interaction of psoriasin with Jab1. Some of the many functions attributable to Jab1 are an increase in AP-1 mediated gene transcription (Nature. 1996 Oct 3;383(6599):453-7). I have therefore conducted a preliminary experiment confirming psoriasin's interaction with Jab1 in yeast (Fig1 a) and invivo by co-immunoprecipitation (Fig1 b).

We are therefore very interested in pursuing the psoriasin-Jab1 interaction further as outlined in the below proposed revision of the statement of work. We have submitted the proposed changes to the Statement of Work to the Grants Officer.

- AIM 1.
- 12-18 Co-localize Jab1 and psoriasin in breast cells and study biochemical interaction co-immunoprecipitation.
- 18-24 Determine if psoriasin has effects on functions of Jab1 such as AP-1 activity and p27 degradation in psoriasin transfected breast cells.
- AIM 2
- 24-36 Define psoriasin's structural binding site for Jab1 by site directed mutagenesis to prove interaction.
- AIM 3
- 24-36 Examine cell type, localization and level of expression of Jab1 in relation to psoriasin expression by immunohistochemistry in breast tumors to correlate Jab1's location and expression in relation to psoriasin.
-

# Figure 1



## **Key Research Accomplishments**

- Psoriasin interacts with RanBPM invitro
- RanBPM mRNA is more highly expressed in cancer cell lines
- RanBPM is expressed in breast cancer tumors

## **Reportable Outcomes**

### **Manuscripts submitted:**

- 1) RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. Ethan D Emberley, R Daniel Gietz, J Darren Campbell, Kent T HayGlass, Leigh C Murphy, Peter H Watson.

### **Abstracts:**

- 1) University of Manitoba Research Day-  
Psoriasin (S100A7) Influences Progression in Breast Cancer. Ethan D. Emberley, Yulian Niu, Ladislav Tomes, Catherine Njue, Erich V. Kliewer, Etienne Leygue, R. Daniel Gietz, Leigh C. Murphy, Peter H. Watson
- 2) Oncogenomics 2002-  
Psoriasin (S100A7) Influences Malignant Progression in Breast Cancer  
Ethan Emberley, Yulian Niu, Leigh Murphy, Peter Watson,

## Conclusion

To pursue the role of psoriasin (S100A7) expression in breast cancer we sought interacting proteins in breast epithelial cells using the yeast 2-hybrid assay. We have identified RanBPM as a potential interacting protein and confirmed this interaction by in vitro assay. Study of cell lines and breast tumors shows that RanBPM mRNA is widely expressed and that while RanBPM expression shows no specific relationship with markers of differentiation or prognosis, high levels of expression of both genes is present in some tumors, and a strong association exists between the psoriasin/RanBPM ratio and both ER/PR status and inflammatory cell infiltrates within the tumor.

Further studies are needed to confirm the psoriasin-RanBPM interaction in vivo. Once this interaction is confirmed, its importance can be examined do determine its role in influencing breast cancer progression. This can be done by measuring the invasiveness of cells where the interaction takes place, as well as inhibiting the interaction to reverse any new phenotypes.

# **RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer**

Ethan D Emberley<sup>1,2</sup>, R Daniel Gietz<sup>2</sup>, J Darren Campbell<sup>3</sup>, Kent T HayGlass<sup>3</sup>, Leigh C Murphy<sup>2</sup>, Peter H Watson<sup>1</sup>.

<sup>1</sup>Department of Pathology, University of Manitoba, Winnipeg Manitoba, Canada, R3E 0W3

<sup>2</sup>Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg Manitoba, Canada, R3E 0W3

<sup>3</sup>Department of Immunology, University of Manitoba, Winnipeg Manitoba, Canada, R3E 0W3

## **Abstract**

### **Background**

Psoriasin has been identified as a gene that is highly expressed in pre-invasive breast cancer, but is often downregulated with breast cancer progression. It is currently unknown whether psoriasin is influencing epithelial cell malignancy directly or effecting the surrounding environment, however the protein is found in the nucleus, cytoplasm as well as extracellularly. In the present study we have sought to identify potential psoriasin-binding proteins and describe their expression profile in breast tumors.

### **Results**

We have identified RanBPM as an interacting protein by the yeast two-hybrid assay and confirmed this interaction in-vitro by co-immunoprecipitation. RT-PCR analysis of RanBPM mRNA expression in cell lines (n=13) shows that RanBPM is widely expressed in different cell types and that expression is higher in tumor compared to normal breast epithelial cell lines. RanBPM expression can also be induced in peripheral blood mononuclear cells by treatment with PHA. RanBPM mRNA is also frequently expressed in invasive breast carcinomas (n=64) and a higher psoriasin/RanBPM ratio is associated with both ER negative (p<0.0001) and PR negative status (p<0.001), and inflammatory cell infiltrates (p<0.0001) within the tumor.

### **Conclusion**

These findings support the hypothesis that psoriasin may interact with RanBPM and this may influence both epithelial and stromal cells and contribute to breast tumor progression.

## Background

We have previously identified the psoriasin gene (S100A7) as highly expressed in pre-invasive breast cancer and subsequently found that persistent psoriasin expression in invasive breast cancer is associated with markers of poor prognosis[1]. The S100 proteins are calcium-binding proteins that may influence several cellular activities such as growth, chemotaxis, adhesion and cytoskeletal activity[1-3]. The function of psoriasin and its influence in breast cancer is unknown. However *in vitro* and *in vivo* study of its role in psoriasis[4] and also in breast tumors[1] suggests that one possible role may be to influence the inflammatory response as a secreted chemotactic factor. We[1] and others[5] have also observed nuclear and cytoplasmic expression within squamous and breast epithelial cells which raises the possibility of an additional function within epithelial cells. We therefore sought to pursue a possible intracellular function by utilizing the yeast 2-hybrid approach to screen a normal human breast expression library for intracellular breast epithelial proteins that might interact with psoriasin and that might offer insights into its functional role in breast tumor progression.

## Methods

**Yeast 2-Hybrid Library Screen-** The full-length psoriasin coding sequence was cloned in frame with the Gal4 DNA Binding Domain (BD) of the Bait plasmid pGBT9 (Clontech) by PCR. pGBT9-psor was transformed into *Saccharomyces cerevisiae* strain KGY37 (supplied by R.D. Gietz) followed by growth on selective media. Expression of the psoriasin fusion protein was confirmed by Western Blot (data not shown). A normal human mammary gland cDNA Prey library (Clontech) was screened for proteins that potentially interact with psoriasin. We screened  $1.7.3 \times 10^7$  clones (4X the complexity of the library) and 242 colonies were picked to assay for expression of the LacZ reporter gene. Clones showing positive LacZ expression had the library plasmid isolated to test for the specificity of their interaction with psoriasin.

**Immunoprecipitation-** Full-length psoriasin coding sequence cloned into pcDNA3.1 (InVitrogen), and RanBPM (amino acids 230-730) cloned into pcDNA4 HisMax (InVitrogen) in-frame with the N-terminal His-Xpress epitope tag.  $^{35}\text{S}$ -Met labelled protein was generated using the Wheat Germ TNT kit for psoriasin and Rabbit Reticulocyte TNT kit for RanBPM according to manufacture's protocol (Promega). Labeled proteins were co-immunoprecipitated in buffer (50mM Tris-HCl pH 7.5, 137mM NaCl, 0.05mM  $\text{CaCl}_2$ , 0.05% Triton X-100) using anti-HisG antibody (InVitrogen). Samples were electrophoresed through a 15% Tris-Tricine polyacrylamide gel as previously described[1]. The gel was then dried and autoradiography to detect labeled proteins.

**Cell lines and Tumor tissue samples-** Peripheral blood leucocytes were obtained from five healthy subjects by venepuncture and cultured as previously described[6] Breast cancer cell lines were obtained from the ATCC and were cultured as previously described[1] in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin and L-Glutamine. MCF10A cells were the kind

gift of Dr. Fred Miller (Wayne State University, Detroit MI). All cells were grown at 37°C in a humidified atmosphere of 95% air and 5% CO<sub>2</sub>. Breast tumor cases were selected from the Manitoba Breast Tumor Bank (Winnipeg, Manitoba, Canada), which operates with ethical approval from the University of Manitoba's Ethics Board and processed previously described[7]. Tumors with estrogen and progesterone receptor levels above 3 fmol/mg total protein and 15 fmol/mg total protein, respectively, were considered ER or PR positive.

The study cohort comprised 64 invasive carcinomas selected to represent a range of tumor types and on the basis of high tissue quality, presence of invasive tumor within >35% of the cross section of the frozen block and minimal (<5%) normal or *in situ* epithelial components. The study group included different invasive tumor types (34 ductal, 13 lobular, and 17 'special type' tumors), and a range of ER status (19 negative, 45 positive), PR status (30 negative, 34 positive) and stages (37 node negative, 27 node positive).

**Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis-** RT-PCR was performed on extracted total RNA (200ng) that was reverse transcribed as described previously[8]. Real-time Quantitative PCR and analysis was performed with the Roche LightCycler. Each PCR reaction was performed in a total volume of 20 µl and consisted of 0.2 µl of each sense and anti-sense primer at 50 µM, 1.6 µl of 25 µM MgCl<sub>2</sub>, 15 µl H<sub>2</sub>O, 2 µl Master Mix (LightCycler- DNA Master SYBR Green I) and 1 µl cDNA template.

The psoriasin primers were sense (5'-AAG AAA GAT GAG CAA CAC-3') and antisense (5'-CCA GCA AGG ACA GAA ACT-3') corresponding to the cDNA sequence. RanBPM primers were sense (5'-CGC ACA TTT TTC AGG TTT-3') and antisense (5'-CTT GCC ACA GTC TCT CCT T-3'). Cyclophilin 33 was used as a loading control for analysis of RanBPM in cell lines and PBMCs using sense (5'-GCT GCG TTC ATT CCT TTT G-3') and antisense (5'-CTC CTG GGT CTC TGC TTT G-3'). All PCR primers were designed to span at least one intron-exon boundary to prevent amplification of possible genomic DNA contamination. For PCR amplification in the LightCycler melting curve analysis was performed at the end of the cycling program to confirm specificity of amplification. Psoriasin, cyclophilin 33 and RanBPM PCR products were each cloned into pGEM-T Easy (Promega), sequenced and then serially diluted separately to construct the standard curve used for quantification of mRNA expression.

Tumors from each cohort were processed as a batch, from frozen sectioning to RNA extraction, reverse transcription in duplicate and then duplicate PCRs from each RT reaction. Controls included RT- and RNA- controls. RNA from PBMLs of five subjects were collected from 3x10<sup>6</sup> cells after 24-hour treatment (10 µg/ml PHA, 0.1ng/ml TSST-1, 30 ng/ml anti-CD3, 10 ng/ml LPS and SAC stimulation at 0.0025% and 0.00025%) as well as unstimulated cells grown for 24 hours in media alone. All RNA isolations were performed using Tri-reagent according to the manufacture's directions (Sigma).

**Statistical Analysis-** For statistical analysis, psoriasin and RanBPM mRNA levels and the psoriasin/RanBPM ratio were assessed either as a continuous variable or

transformed into low or high expression categories using the 75th percentile as a cutpoint for all variables. This cutpoint was selected as it corresponded to the minimum mRNA level at which psoriasin protein could be detected by Western blot analysis of frozen sections from a subset of the tumors (Data not shown). Correlations were tested using Spearman's test and associations with categorical variables were tested by Chi-squared test. For induction of RanBPM in PBMC, one-way ANOVA (nonparametric) analysis was performed on the means of duplicate Reverse Transcription samples for selected treatments.

## Results

**Yeast 2-Hybrid Screen and Identification of True Positives-** The yeast Bait vector pGBT9-psoriasin was used to screen a normal human mammary gland cDNA expression library (Clontech) to identify potential proteins with which psoriasin forms a physical interaction. Clones that grew on selection media were isolated and examined for the strength and specificity of their interaction with psoriasin. Four clones were identified that specifically interacted with psoriasin in the yeast system. We pursued the interaction of RanBPM (clone 6-3) with psoriasin as it presented the strongest interaction, as determined by the intensity of activation of the reporter gene LacZ (data not shown). Psoriasin was demonstrated to specifically interact with RanBPM in the yeast system (Figure 1).

**Co-Immunoprecipitation of psoriasin and RanBPM-** Both psoriasin and RanBPM were cloned by PCR into their respective expression vectors downstream of a T7 promoter and <sup>35</sup>S-Met labeled proteins were generated. The radiolabelled proteins were immunoprecipitated by addition of anti-HisG antibody, which specifically detects the His-tagged RanBPM protein. As shown (Figure 2), the protein-protein interaction observed in yeast was confirmed by these co-immunoprecipitation studies.

**Cell line expression-** RanBPM mRNA expression was assessed by RT-PCR in established fibroblast and epithelial cell lines and in freshly obtained peripheral blood mononuclear cells (Figure 3). RanBPM was detected in all cells and the relative levels differed between cell types. Amongst the established cell lines there was no significant difference between fibroblasts, normal epithelial cells and Ras-transformed derivatives of the same normal epithelial cell. RanBPM expression was consistently higher in tumor cell lines compared to normal cells ( $p=0.0007$ ), with up to a 3-fold difference in levels. Within the set of 5 breast tumor cell lines examined, no relationship with ER status or epithelial differentiation was evident. Psoriasin expression was undetectable or very low in all cell lines (data not shown).

RanBPM expression was also examined in primary cultures of peripheral blood mononuclear cells. In experiments with samples from 5 healthy subjects, RanBPM mRNA was strongly induced in cells following 24-hour stimulation with the polyclonal activator PHA ( $p<0.001$ ). PHA elicits dominantly Th2 associated cytokine response[6]. In contrast, cells stimulated by polyclonal activators that elicit Th1 dominated immunity (anti-CD3, TSST-1) or cytokine production by antigen presenting cells that is Th1 inducing (LPS, SAC), an increase in RanBPM expression was weak to undetectable (Figure 4). No significant differences were apparent in RanBPM expression between male ( $n=3$ ) and female ( $n=2$ ) subjects in this sample.

**Tumor expression-** The relationship between RanBPM, psoriasin, the psoriasin/RanBPM ratio and indicators of differentiation and prognosis was examined in a series of 64 invasive breast tumors by quantitative RT-PCR (Table 1). Higher levels of expression of either RanBPM or psoriasin were present in only 16/64 and 16/64 tumors respectively, however high levels of expression of both genes was observed to coincide in 4/64 cases. This small subset of cases showed no significant distinguishing clinical features. Higher RanBPM mRNA levels were seen in association with ER positive status and low inflammation. However there was no significant difference in RanBPM mRNA expression with any parameter including indicators of differentiation (ER, PR, tumor type or grade) or stage (tumor size and nodal status) or with cellular composition of the tumor section (inflammation and proportion of epithelial tumor cells and stroma). At the same time higher levels of psoriasin expression were significantly associated with ER negative and PR negative status and inflammation (Table 1). The psoriasin/RanBPM ratio showed even stronger and highly significant associations with the same three parameters, and it was also higher in medullary carcinomas compared to other special type tumors (mucinous and tubular), lobular, and ductal carcinomas ( $p=0.0313$ ).

## Discussion

To pursue the role of psoriasin (S100A7) expression in breast cancer we sought interacting proteins in breast epithelial cells using the yeast 2-hybrid assay. We have identified RanBPM as a potential interacting protein and confirmed this interaction by *in vitro* assay. Study of cell lines and breast tumors shows that RanBPM mRNA is widely expressed and that while RanBPM expression shows no specific relationship with markers of differentiation or prognosis, high levels of expression of both genes is present in some tumors, and a strong association exists between the psoriasin/RanBPM ratio and both ER/PR status and inflammatory cell infiltrates within the tumor.

The biological role of psoriasin in breast tumors is not known, however it may be related to aspects of tumor progression. This role might be mediated either through an indirect influence on the host immune response or through a more direct influence on the epithelial tumor cell. The first hypothesis is supported by correlations between psoriasin and the intensity of the host inflammatory cell response within invasive breast tumors[1] and *in vitro* effects as a secreted chemotactic factor for T-cells[4]. The second hypothesis is supported by evidence that psoriasin may not only be secreted[9,10] but also can be localized in both nuclear and cytoplasmic epithelial cell compartments in normal skin and breast tumors[1]. Other secreted S100 proteins have also been localized to cytoplasm and nucleus[11] and altered subcellular localization in disease has also been observed with a keratinocyte S100 related protein, profilaggrin[12,13].

RanBPM was originally described as a Ran binding protein that is highly conserved between human, mouse and hamster, and detectable in both skin fibroblast and HeLa cell lines[14]. However, more recently it has been found that the original study had centered on a N-terminally truncated cDNA and that the full size RanBPM cDNA encodes a larger 90kDa protein that localizes to both the nucleus and also to the peri-nuclear and peri-centrosomal cytoplasmic region in HeLa cells[15]. While RanBPM

was identified through its ability to interact with the Ran nuclear-cytoplasmic transport protein in the yeast system, when overexpressed the c-terminal portion of RanBPM was capable of causing reorganization of the microtubule network and ectopic nucleation of microtubules *in vivo*, and this effect could also be inhibited by GTP-Ran[14]. This is of interest as although Ran is known to play a key role in nuclear transport[16,17], it has also been associated with a variety of additional functions, including cell proliferation and viability in breast cells[18] that may be mediated by interactions with a number of Ran binding proteins. While the full length RanBPM has now been identified, the exact role for this protein in microtubule function remains to be explored. Our findings here confirm that RanBPM is expressed in multiple cell types and show that it may be increased in breast tumor cell lines. In breast tumors higher levels of expression of RanBPM and psoriasin overlapped in some cases. While this small subset of cases showed no significant distinguishing clinical features and there was no association with known prognostic factors, the expression of RanBPM was inversely related to psoriasin. There was also a tendency to higher levels of RanBPM in association with ER positivity and low levels of inflammation, leading to highly significant differences in the psoriasin/RanBPM ratio in tumors that differed by ER status and extent of inflammation. This latter association is also supported by the higher psoriasin/RanBPM ratio found in medullary carcinomas compared to other invasive tumors, where higher levels of inflammation are inherent in the diagnosis of this special tumor type. Our data also suggests that RanBPM is rapidly expressed by primary PBMC, in particular upon stimulation leading to type 2 immunity. This raises the possibility that RanBPM could be a target for mediating the actions of secreted psoriasin, perhaps affecting T cell trafficking to activated or inflamed sites.

Psoriasin has also been found to interact with two other proteins. It is a substrate for transglutaminases TG1 and TG2[19], and a binding partner for epidermal fatty acid binding protein (E-FABP) in epidermis[5]. Transglutaminases are expressed in both epithelium and inflammatory cells and their cross linking capacity is associated with a range of functions including apoptosis and terminal differentiation in keratinocytes, cross linking of extracellular matrix proteins, and interaction with integrins to mediate adhesion and motility of monocytic cells[20]. The FABP proteins have also been implicated in terminal differentiation in both epidermis and breast epithelium where overexpression of H-FABP and B-FABP can both cause growth inhibition and reduction of tumorigenicity in mammary carcinoma cells. In the CNS, B-FABP has also been implicated in the control of the glial fibre system and neuronal migration. RanBPM is a third interacting protein, that is expressed in several cell types, is induced in PHA stimulated peripheral blood leucocytes, and when overexpressed as a truncated protein can affect microtubule function. The interaction with psoriasin may just reflect a common mode of intracellular transport. However, one common functional association to these three interacting proteins is an involvement in cytoskeletal functions, adhesion, and migration. Alterations of adhesion and polarity are associated with the progression of breast cancer and are inherent in the process of invasion. While psoriasin expression in keratinocytes[21] is associated with changes in adhesion, it remains to be determined if manipulation of psoriasin in squamous and breast epithelial cells can directly influence cell adhesion.

In conclusion, we have shown that psoriasin interacts with an intracellular protein, RanBPM *in-vitro*. Further study to confirm the interaction *in-vivo* and explore the

biological role of RanBPM in breast and inflammatory cells may help to elucidate the role of psoriasin in breast cancer.

## Competing interests

None declared

## Acknowledgements

E.D.E. is the recipient of a U.S. Army Medical Research and Materiel Command Predoctoral Traineeship Award. Grant Number: DAMD17-00-1-0320.

## References

1. S Al Haddad, Z Zhang, E Leygue, L Snell, A Huang, Y Niu, T Hiller-Hitchcock, K Hole, LC Murphy, PH Watson: **Psoriasin (S100A7) expression and invasive breast cancer.** *Am J Pathol* 1999, **155**: 2057-2066.
2. R Donato: **S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.** *Int J Biochem Cell Biol* 2001, **33**: 637-668.
3. CW Heizmann, JA Cox: **New perspectives on S100 proteins: a multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family.** *Biometals* 1998, **11**: 383-397.
4. T Jinquan, H Vorum, CG Larsen, P Madsen, HH Rasmussen, B Gesser, M Etzerodt, B Honore, JE Celis, K Thestrup-Pedersen: **Psoriasin: a novel chemotactic protein.** *J Invest Dermatol* 1996, **107**: 5-10.
5. G Hagens, K Roulin, R Hotz, JH Saurat, U Hellman, G Siegenthaler: **Probable interaction between S100A7 and E-FABP in the cytosol of human keratinocytes from psoriatic scales.** *Mol Cell Biochem* 1999, **192**: 123-128.
6. V Gangur, FE Simons, KT Hayglass: **Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses.** *FASEB J* 1998, **12**: 705-713.
7. T Hiller, L Snell, PH Watson: **Microdissection RT-PCR analysis of gene expression in pathologically defined frozen tissue sections.** *Biotechniques* 1996, **21**: 38-40, 42, 44.
8. E Leygue, L Snell, T Hiller, H Dotzlaw, K Hole, LC Murphy, PH Watson: **Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma.** *Cancer Res* 1996, **56**: 4606-4609.

9. P Madsen, HH Rasmussen, H Leffers, B Honore, K Dejgaard, E Olsen, J Kiil, E Walbum, AH Andersen, B Basse et al.: **Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin.** *J Invest Dermatol* 1991, **97**: 701-712.
10. JE Celis, HH Rasmussen, H Vorum, P Madsen, B Honore, H Wolf, TF Orntoft: **Bladder squamous cell carcinomas express psoriasin and externalize it to the urine.** *J Urol* 1996, **155**: 2105-2112.
11. E Albertazzi, F Cajone, MS Lakshmi, GV Sherbet: **Heat shock modulates the expression of the metastasis associated gene MTS1 and proliferation of murine and human cancer cells.** *DNA Cell Biol* 1998, **17**: 1-7.
12. BW Schafer, CW Heizmann: **The S100 family of EF-hand calcium-binding proteins: functions and pathology.** *Trends Biochem Sci* 1996, **21**: 134-140.
13. A Ishida-Yamamoto, H Takahashi, RB Presland, BA Dale, H Iizuka: **Translocation of profilaggrin N-terminal domain into keratinocyte nuclei with fragmented DNA in normal human skin and loricrin keratoderma.** *Lab Invest* 1998, **78**: 1245-1253.
14. M Nakamura, H Masuda, J Horii, K Kuma, N Yokoyama, T Ohba, H Nishitani, T Miyata, M Tanaka, T Nishimoto: **When overexpressed, a novel centrosomal protein, RanBPM, causes ectopic microtubule nucleation similar to gamma-tubulin.** *J Cell Biol* 1998, **143**: 1041-1052.
15. H Nishitani, E Hirose, Y Uchimura, M Nakamura, M Umeda, K Nishii, N Mori, T Nishimoto: **Full-sized RanBPM cDNA encodes a protein possessing a long stretch of proline and glutamine within the N-terminal region, comprising a large protein complex.** *Gene* 2001, **272**: 25-33.
16. MS Moore: **Ran and nuclear transport.** *J Biol Chem* 1998, **273**: 22857-22860.
17. D Gorlich: **Nuclear protein import.** *Curr Opin Cell Biol* 1997, **9**: 412-419.
18. J Milano, Jr., DS Strayer: **Effects of overexpression of Ran/TC4 mammalian cells in vitro.** *Exp Cell Res* 1998, **239**: 31-39.
19. M Ruse, A Lambert, N Robinson, D Ryan, KJ Shon, RL Eckert: **S100A7, S100A10, and S100A11 are transglutaminase substrates.** *Biochemistry* 2001, **40**: 3167-3173.
20. U Gunthert, M Hofmann, W Rudy, S Reber, M Zoller, I Hausmann, S Matzku, A Wenzel, H Ponta, P Herrlich: **A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.** *Cell* 1991, **65**: 13-24.
21. BM Schaefer, R Wallich, K Schmolke, W Fink, M Bechtel, J Reinartz, MD Kramer: **Immunohistochemical and molecular characterization of cultured keratinocytes after dispase-mediated detachment from the growth substratum.** *Exp Dermatol* 2000, **9**: 58-64.

## Figures

### Figure 1 - Confirmation of specificity of interactions observed in yeast 2-hybrid assay.

Panels show yeast transformed with a) psoriasin and RanBPM expression plasmids (left) and RanBPM alone (right), and yeast transformed with b) Psoriasin alone, c) psoriasin and empty prey vector, and d) psoriasin with a control gene not isolated in the primary screen. In panels b-d, plates on left are Histidine + (control) and plates on the right are Histidine - (test). Panel a) shows activation of LacZ reporter gene only occurs in yeast transformed with both expression plasmids (left) and no activation in yeast transformed with RanBPM alone (right). Panel b) shows that psoriasin alone cannot activate the Histidine reporter gene as demonstrated by absence of growth on Histidine - plate. Panels c) and d) show that there is a specific interaction necessary for activation of the reporter gene.

### Figure 2 - *In vitro* interaction of psoriasin and RanBPM as determined by co-immunoprecipitation.

Psoriasin (lane 1) and RanBPM (lane 2) <sup>35</sup>S-Met labelled proteins were generated and electrophoresed through a denaturing polyacrylamide gel and detected by autoradiography. Psoriasin binds to and co-immunoprecipitates with RanBPM (lane 4). RanBPM and psoriasin do not bind to protein G-beads on their own, (lane 3 and 5 respectively).


### Figure 3 - RanBPM mRNA expression in selected cell lines.

RanBPM mRNA expression in fibroblasts (CRL and 125), normal mammary epithelia (MCF10ATB, MCF10A1, MCF10AT1), and epithelial carcinoma cell lines from breast (T47D5, MCF-7, 126, MDA-MB-231, BT20) and cervix (HeLa). RanBPM is expressed at higher levels in cells derived from tumors compared to those derived from normal epithelia and stroma. Columns and bars represent means and standard deviations from duplicate experiments. Mann Whitney test was used to compare levels between normal epithelial cells and fibroblasts (\*) or neoplastic epithelial cells (\*\*).


### Figure 4 - RanBPM mRNA expression in peripheral blood mononuclear cells (PBMCs).

RanBPM mRNA expression is strongly induced by stimulation of cells with PHA, weakly induced by TSST-1, but not anti-CD3, LPS or SAC. Columns and bars represent means and standard deviations from duplicate experiments performed on samples from 6 patients.


**Figure 1**




**Figure 2**



**Figure 3**



**Figure 4**



# Table 1

Table 1- Analysis of the Relationship Between RanBPM and psoriasis Expression and Clinical-Pathological Parameters in Human Breast Cancer

		RanBPM			Psoriasis			Psoriasis/RanBPM		
		low	high	p value	low	high	p value	low	high	p value
ER	-ve	16	3	ns	8	11	0.0002	7	12	<0.0001
	+ve	32	13		40	5		41	4	
PR	-ve	23	7	ns	17	13	0.0011	17	13	0.0015
	+ve	25	9		35	3		31	3	
INFL	low	36	15	ns	41	10	0.0485	44	7	<0.0001
	high	12	1		15	6		4	9	
NS	neg	28	9	ns	30	7	ns	27	10	ns
	pos	20	7		18	9		21	6	
GRADE	low	14	3	ns	15	2	ns	15	4	ns
	int	13	5		12	6		13	5	
	high	9	3		9	3		8	4	
SIZE	<=2	11	5	ns	10	3	ns	11	5	ns
	>2	27	12		32	11		32	7	
TYPE	ductal	26	9		26	9		25	9	
	lobular	11	2		11	2		11	2	
	mucinous	3	3		4	1		5	1	
	tubular	4	2		4	2		5	1	
	medullary	5	0		3	2		1	4	